TriSalus Life Sciences, Inc.
TLSIW- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001826667
In the last 90 days, TriSalus Life Sciences, Inc. insiders filed 1 open-market purchase and 3 sales; 5 institutions reported holding it in 13F filings for Q2 2026, worth $798.0K in total; no superinvestor holds it.
Other share classesTLSI
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 11, 2026, 1:16 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $39.2M (86.9% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K/A | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 23, 2025 | Jan 5, 2024 | – | – |
| Revenue | $45.2M | $29.4M | $18.5M | – | – |
| Cost of revenue | $6.96M | $4.10M | $2.60M | – | – |
| Gross profit | $38.2M | $25.3M | $15.9M | – | – |
| Research and development | $15.0M | $17.7M | $29.5M | – | – |
| Selling, general and administrative | $21.5M | $18.0M | $23.5M | $2.75M | $3.04M |
| Operating income | -$26.9M | -$36.2M | -$54.1M | -$2.75M | -$3.04M |
| Interest expense | – | – | $16.0K | – | – |
| Income tax | $7.00K | $6.00K | $9.00K | $570.9K | $0 |
| Net income | -$39.2M | -$30.0M | -$59.0M | $5.54M | $4.77M |
| EPS, basic | $-1.84 | $-1.31 | $-6.73 | – | – |
| EPS, diluted | $-1.84 | $-1.31 | $-6.73 | – | – |
| Weighted shares, basic | 37.9M | 25.3M | 9.40M | – | – |
| Weighted shares, diluted | 37.9M | 25.3M | 9.40M | – | – |
| Margins and growth | |||||
| Gross margin | 84.6% | 86.1% | 85.9% | – | – |
| Operating margin | -59.7% | -122.9% | -292.5% | – | – |
| Net margin | -86.9% | -102.1% | -318.9% | – | – |
| Revenue growth, year over year | +53.4% | +59.0% | – | – | – |
| Net income growth, year over year | – | – | −1,165.8% | +16.2% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022! | FY2021! |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K/A | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 23, 2025 | Jan 5, 2024 | – | – |
| Cash and equivalents | $20.4M | $8.53M | $11.8M | $153.6K | $200.9K |
| Accounts receivable | $6.56M | $5.09M | $3.55M | – | – |
| Inventory | $3.08M | $4.05M | $2.54M | – | – |
| Total current assets | $32.2M | $20.7M | $20.9M | $359.9K | $525.9K |
| Intangible assets | – | – | $1.13M | – | – |
| Total assets | $35.3M | $24.0M | $25.7M | $20.2M | $250.5M |
| Total current liabilities | $11.5M | $10.2M | $14.7M | $2.50M | – |
| Long-term debt | $33.0M | $22.1M | – | – | – |
| Total liabilities | $69.2M | $49.9M | $51.7M | $13.7M | $17.3M |
| Shareholders' equity | -$33.9M | -$25.9M | -$25.9M | -$13.3M | -$16.7M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K/A | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 23, 2025 | Jan 5, 2024 | – | – |
| Operating cash flow | -$18.0M | -$40.8M | -$50.0M | -$2.74M | -$1.74M |
| Capital expenditures | $918.0K | $345.0K | $588.0K | – | – |
| Free cash flow | -$18.9M | -$41.2M | -$50.6M | – | – |
| Depreciation and amortization | $626.0K | $744.0K | $702.0K | – | – |
| Stock-based compensation | $9.13M | $5.44M | $1.40M | – | – |
| Share buybacks | – | – | – | $232.4M | – |
| Investing cash flow | -$838.0K | -$345.0K | -$2.12M | $233.2M | $60.0K |
| Financing cash flow | $30.8M | $37.9M | $54.6M | -$230.5M | $544.0K |
| Net change in cash | $11.9M | -$3.25M | $2.46M | -$47.3K | -$1.13M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 20.2% | 18.5% | 7.6% | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 6, 2026 | 61.7M | +23.5% | SEC |
| Aug 4, 2026 | 61.6M | +23.5% | SEC |
| May 8, 2026 | 61.4M | +62.3% | SEC |
| Mar 2, 2026 | 61.3M | +90.0% | SEC |
| Nov 10, 2025 | 50.0M | +63.9% | SEC |
| Aug 6, 2025 | 49.9M | +70.1% | SEC |
| May 9, 2025 | 37.8M | +39.3% | SEC |
| Mar 31, 2025 | 32.3M | +20.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- A column marked ! failed an accounting identity (gross profit = revenue − cost of revenue, or assets = liabilities + equity, within 1%). Its numbers are shown as filed.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.